Piramal Pharma Shares Surge 3% After Reaffirming FY26 Guidance
Market
C
CNBC TV18•29-01-2026, 10:12
Piramal Pharma Shares Surge 3% After Reaffirming FY26 Guidance
- •Piramal Pharma shares recovered from early lows, surging 3% after the company reaffirmed its FY26 guidance.
- •Despite a weak Q3FY26 performance with a net loss of ₹136.2 crore and revenue decline, the company maintains a positive long-term outlook.
- •The company expects the March quarter to be its strongest, continuing historical trends.
- •Segment-wise, CDMO revenue declined 9%, hospital generics grew 2%, and consumer healthcare saw a strong 20% growth.
- •Performance was impacted by inventory destocking, slower early-stage order inflows, and regulatory delays, but recovery signs are noted since October 2025.
Why It Matters: Piramal Pharma shares rebounded as the company reaffirmed its FY26 guidance despite recent weak results.
✦
More like this
Loading more articles...
